Follow PTGX's trial news. Pro members can get an alert when Protagonist Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 2% on Nov 6 while the S&P 500 rose 0.3%.
Up 804% over the three years to Nov 9 while the S&P 500 rose 80%; down 2% on Nov 6.
2 reasons, from its filings, with the timeline, for Pro members.
| The company | Sales up 164% on the year |
| Latest filing | 10-Q, Nov 6 |
Thu Nov 12: Truist Securities BioPharma…Investor conference · date confirmed.
3 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed +2.6% on average, higher 3 of 4 times.
CFO Asif Ali sold 58,629 shares on Sep 30, under a planned sale. 20 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Above Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means
PTGX is #35 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 35 |
Net income over four quarters: PTGX $342M, BHVN -$543M, SEPN -$59.0M, IRON -$243M.
Expected to report Thu Feb 25, after the close (in 107 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A profit of $3.07 a share, from a loss of $0.62.
“This revenue was primarily driven by the proportional recognition of $266.6 million related to the $275.0 million earned from Takeda during the quarter.”
PTGX's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“We expect our R&D expenses to increase for the remainder of the year as compared to the prior quarters in 2026.”
From its results filing (SEC filing · Nov 5)
Its share count grew 13% a year over 5 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | 0.0% | -2.4% | not yet |
| Aug 5, 2026 | +5.6% | +6.5% | +10.7% |
| May 5, 2026 | +3.8% | +4.8% | +0.8% |
Sales grew in three of the last seven years, to $46M in 2025. It lost money in 2025 after a profit in 2024.
RSI 45.6, MACD below signal, below its 50-day, above its 200-day. Not scored.
2 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: PTGX is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
“The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change.”
PTGX scores 12 today, which Breakaway calls Above Average. It is #35 of 281 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 2% on Nov 6 while the S&P 500 rose 0.3%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
PTGX scores 12 today, which Breakaway calls Above Average (11 to 14). That is #35 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PTGX's 12.
Expected to report Thu Feb 25, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. PTGX closed higher after 3 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Thursday morning. No account. No card. Then keep going with a free account.